Amantadine Revisited: A Contender for Initial Treatment in Parkinson’s Disease?

Sarah Marmol(University of Miami), Jason Margolesky(University of Miami), Matthew Feldman(University of Miami), Carlos Singer(University of Miami Health System)

CNS Drugs

October 14, 2021

10.1007/s40263-021-00862-5

Cited by 23

Related Papers

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease

|JAMA|2016|397

Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder

|Sleep Medicine|2013|391

Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group

|Sleep Medicine|2013|238

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease

|Neurology|2016|137

Genotype–Phenotype Relations in Primary Familial Brain Calcification: Systematic <scp>MDSGene</scp> Review

|Movement Disorders|2021|93